Discussion  by unknown
ai
a
F
m
a
t
a
a
M
t
a
t
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
D
D
u
d
t
t
i
a
T
i
p
e
e
c
o
y
s
t
i
p
v
p
t
o
b
Cardiothoracic Transplantation Chang et al
5
TXnd interpretation of the data. Drs Chan, Lama, and Lau provided
nput on the study design, interpretation of data, and reviewed and
pproved the final manuscript. Drs Flaherty and Pickens and Ms
lorn provided and cared for study patients and approved the final
anuscript. Dr Murray and Mr Lonigro performed the statistical
nalyses, helped organize the content, and reviewed and approved
he final manuscript. Drs Martinez and Orringer supervised the
cquisition and interpretation of the data, provided critical input,
nd approved the final manuscript.
We acknowledge G. Michael Deeb, MD, Mark D. Iannettoni,
D, and Joseph P. Lynch III, MD, for their past contributions to
he University of Michigan pulmonary transplantation program,
nd Ms Jennifer Berry for her ongoing dedication to data collec-
ion and database maintenance.
eferences
1. Sundaresan S, Semenkovich J, Ochoa L, Richardson G, Trulock E,
Cooper J, et al. Successful outcome of lung transplantation is not
compromised by the use of marginal donor lungs. J Thorac Cardio-
vasc Surg. 1995;109:1075-80.
2. Pierre A, Sekine Y, Hutcheon M, Waddell T, Keshavjee S. Marginal
donor lungs: a reassessment. J Thorac Cardiovasc Surg. 2002;123:
421-8.
3. Egan TM. Non-heart-beating donors in thoracic transplantation.
J Heart Lung Transplant. 2004;23:3-10.
4. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz
MI. Registry of the International Society for Heart and Lung Trans-
plantation: Twenty-second official adult lung and heart-lung transplant
report—2005. J Heart Lung Transplant. 2005;24:956-67.
5. Murray S, Merion RM, McCullough KP, Bustami RT, Gillespie BW,
Wolfe RA, et al. Diagnosis-based models of lung transplant waiting
list mortality. Am J Transplant. 2002;2(s3):270 (abstract 524).
6. International guidelines for the selection of lung transplant candidates:
The American Society for Transplant Physicians (ASTP)/American
Thoracic Society (ATS)/European Respiratory Society (ERS)/Interna-
tional Society for Heart and Lung Transplantation (ISHLT). Am. J.
Respir. Crit. Care Med. 1998;158:335-9.
7. Cox DR. Regression models and life-tables. J R Statist Soc B. 1972;
34:187-220.
8. Burton CM, Milman N, Carlsen J, Arendrup H, Eliasen K, Andersen
CB, et al. The Copenhagen National Lung Transplant Group: survival
after single lung, double lung, and heart-lung transplantation. J Heart
Lung Transplant. 2005;24:1834-43.
9. de Perrot M, Chaparro C, McRae K, Waddell TK, Hadjiliadis D,
Singer LG, et al. Twenty-year experience of lung transplantation at a
single center: influence of recipient diagnosis on long-term survival.
J Thorac Cardiovasc Surg. 2004;127:1493-501.
0. Meyers BF, Lynch J, Trulock EP, Guthrie TJ, Cooper JD, Patterson
GA. Lung transplantation: a decade of experience. Ann Surg. 1999;
230:362-70.
1. Harringer W, Wiebe K, Struber M, Franke U, Niedermeyer J, Fabel H,
et al. Lung transplantation—10-year experience. Eur J Cardiothorac
Surg. 1999;16:546-54.
2. Pielsticker EJ, Martinez FJ, Rubenfire M. Lung and heart-lung trans-
plant practice patterns in pulmonary hypertension centers. J Heart
Lung Transplant. 2001;20:1297-304.
3. Aris RM, Routh JC, Lipuma JJ, Heath DG, Gilligan PH. Lung trans-
plantation for cystic fibrosis patients with Burkholderia cepacia com-
plex. Survival linked to genomovar type. Am J Respir Crit Care Med.
2001;164:2102-6.
4. Egan TM, Detterbeck FC, Mill MR, Bleiweis MS, Aris R, Paradowski
L, et al. Long term results of lung transplantation for cystic fibrosis.
Eur J Cardiothorac Surg. 2002;22:602-9.5. Meyer DM, Bennett LE, Novick RJ, Hosenpud JD. Single vs bilateral,
sequential lung transplantation for end-stage emphysema: influence of g
38 The Journal of Thoracic and Cardiovascular Surgery ● Febrrecipient age on survival and secondary end-points. J Heart Lung
Transplant. 2001;20:935-41.
6. Cassivi SD, Meyers BF, Battafarano RJ, Guthrie TJ, Trulock EP,
Lynch JP, et al. Thirteen-year experience in lung transplantation for
emphysema. Ann Thorac Surg. 2002;74:1663-70.
7. Hosenpud JD, Bennett LE, Keck BM, Edwards EB and Novick RJ.
Effect of diagnosis on survival benefit of lung transplantation for
end-stage lung disease. Lancet. 1998;351:24-7.
8. Pochettino A, Kotloff RM, Rosengard BR, Arcasoy SM, Blumenthal
NP, Kaiser LR, et al. Bilateral versus single lung transplantation for
chronic obstructive pulmonary disease: intermediate-term results. Ann
Thorac Surg. 2000;70:1813-9.
9. Merion RM, Hulbert-Shearon TE, Bustami RT, Garrity ER, Egan TM,
Port FK, et al. Proposed lung allocation system based on medical
urgency and transplant benefit. Am J Transplant. 2004;4(s8):414 (ab-
stract 936).
0. Novick RJ, Stitt LW, Al-Kattan K, Klepetko W, Schafers HJ, Duch-
atelle JP, et al. Pulmonary retransplantation: predictors of graft func-
tion and survival in 230 patients. Pulmonary Retransplant Registry.
Ann Thorac Surg. 1998;65:227-34.
1. Strueber M, Fischer S, Gottlieb J, Simon AR, Goerler H, Gohrbandt B,
et al. Long-term outcome after pulmonary retransplantation. J Thorac
Cardiovasc Surg. 2006;132:407-12.
2. Meyers B, Lynch J, Trulock E, Guthrie T, Cooper J, Patterson G.
Single versus bilateral lung transplantation for idiopathic pulmonary
fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg.
2000;120:99-107.
3. Meyer DM, Edwards LB, Torres F, Jessen ME, Novick RJ. Impact of
recipient age and procedure type on survival after lung transplantation
for pulmonary fibrosis. Ann Thorac Surg. 2005;79:950-7.
4. Hardy JD. The first lung transplant in man (1963) and the first heart
transplant in man (1964). Transplant Proc. 1999;31:25-9.
iscussion
r Shaf Keshavjee (Toronto, Ontario, Canada). I congrat-
late the authors on an excellent collection of their data
emonstrating continuously improved outcomes after lung
ransplantation in their institution.
As you know, we in Toronto also favor bilateral lung
ransplantation strongly, with 80% to 90% of our transplants
n our entire program being bilateral lung transplants. In
ssessing the results of bilateral lung transplantation from
oronto, St Louis, and Duke University, we found a signif-
cant functional and survival benefit for bilateral lung trans-
lantation over single lung transplantation in patients with
mphysema, but in the other disease categories the differ-
nce was less obvious.
In looking at your data, I have trouble reconciling your
onclusion with your own experience. You report that 75%
f your patients underwent transplantation for emphysema,
et when you analyzed that group you did not show a
ignificant advantage of bilateral over single lung transplan-
ation. I think your single lung transplant group was signif-
cantly disadvantaged in that the single lung transplant
atients in your institution were a full decade older. Having
ery high-risk recipients, that is, a single lung transplant for
ulmonary hypertension, also disadvantaged the single lung
ransplant group. So, your bilateral group had the advantage
f those 16 patients with cystic fibrosis who received a
ilateral lung transplant and your single lung transplant
roup had the disadvantage of 15 patients with pulmonary
uary 2007
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TXypertension and a 33% mortality. Did you analyze the
ilateral versus single transplant results by excluding that
ery high-risk group of single lung transplants for pulmo-
ary hypertension?
Dr Chang. Dr Keshavjee, thank you for your comments
nd insight. First, as an aside, I would like to point out that
t has been about 20 years to the day since the Toronto
roup published the results of their initial experience in the
ew England Journal of Medicine. That was with single
ransplantation for idiopathic pulmonary fibrosis. It is from
he successes and scientific inquiry of the Toronto, Barnes,
uke, and other major transplant centers that we hope to
uild our own program.
We did not exclude the patients undergoing single
ung transplant for pulmonary hypertensive disorders for
his presentation. I suspect that if we excluded that high-
isk group, as well as the 16 patients who underwent
ilateral transplantation for cystic fibrosis or immune-
elated bronchiectasis, we might see equalization of the
urvival curves. We looked at the patients undergoing
ingle or bilateral transplantation in group A, the patients
ith obstructive lung disease, and we did not observe a
ignificant difference in overall survival, with a P value of
07. That could be due to our distribution, which is weighted
eavily toward single lung transplantation so that we did not
ave enough numbers in our bilateral group to determine
ny statistical significance.
Dr Keshavjee. I am also interested in your comment
bout bilateral thoracotomies, posterolateral thoracotomies,
nd 4 intraoperative deaths. How many patients had bilat-
ral thoracotomies, and were those intraoperative deaths
elated to that?
Dr Chang. No, to my recollection we did not have an
perative death resulting from the patients being flipped
rom one side to the other.
Dr Keshavjee. My last question concerns your use of
ntravenous cyclosporine. Do you still do that? Most people
ave switched to using oral cyclosporine for a number of
dvantages related to achieving therapeutic levels and bio-
ogic activity.
Dr Chang. We used intravenous cyclosporine in the
mmediate postoperative period and transitioned to oral
ormulation, more recently Neoral, when patients were tol-
rating oral intake. More recently, we have stopped using
yclosporine completely, instead using tacrolimus either
ublingually or orally. Among the many reasons for which
e performed this study, with the initiation of the lung
llocation scoring system, we wanted to review our own
rior experience for future comparison. Having done this
nd with the addition of a new partner to our surgical group,
e found that we were holding calcineurin inhibitor therapy
intravenous cyclosporine) when patients had increased risk
or postoperative renal dysfunction. Since undertaking this g
The Journal of Thoracictudy we have switched over to tacrolimus, mycophenolate
ofetil, as well as steroids for our posttransplant immuno-
uppression regimen.
Dr Frederick L. Grover (Denver, Colo). This is
lways an interesting topic, and I know Shaf and Alec
nd I go round and round about this. At Colorado we
ave taken the attitude of single lung transplantation for
diopathic pulmonary fibrosis and for chronic obstructive
ulmonary disease in the older age groups, which gener-
lly we define as late 50s and 60s or 70s, partly depend-
ng on how frail the patients are as well. We have had
elatively good results with that plan. The way I always
ry to balance this is the shortage of organ donors and the
isk of death on the waiting list versus perhaps some
urvival advantage and quality of life advantage on pa-
ients with double lung versus single lung transplantation.
ndeed, when we were developing the scoring system for
ung allocation, we tried to weigh the risk of death on the
aiting list against the risk of an adverse outcome after
he lung transplant itself.
Have you taken into account, if you were to do double
ransplants, potentially how many patients on the waiting
ist might not get to transplantation and what would their
isk of dying be? I think you have to look at this more in
he whole public health type of big picture.
Dr. Chang. Thank you for your comments, Dr Grover, and
articularly for your contributions as part of the SRTR group
hat developed the lung allocation scoring system.
As far as how implementation of the lung allocation
coring system will affect our decisions to use bilateral
ransplantation, it is hard for me to predict what will happen
o our waiting list mortality. Our waiting list mortality
enerally runs about 10% to 20%, comparable to the waiting
ist mortality reported by Dr De Perrot. I do not know what
s going to happen as far as trying to increase the number of
ilateral transplants in our group further. That is a major
eason why we undertook this study, to see whether we
ould identify factors driving our decision to proceed with
ither single or bilateral transplant and to establish an in-
ernal benchmark, if you will, for our future efforts.
Dr Joshua R. Sonett (New York, NY). Let me ask one
uestion. In lieu of your data, with the new lung alloca-
ion scoring system, it appears, at least from our early
xperience, that it is harder for us to get lungs for even
elatively sick patients with pulmonary hypertension.
hat was your policy, or how do you think your group
ould work right now? Would you still use a single
ransplant or would you go with doubles for the pulmo-
ary hypertensive groups, even with the difficulty of
etting organs for them?
Dr Chang. Our preference has been recently for bi-
ateral transplants in the pulmonary arterial hypertension
roup, and we have observed the same thing, that their
and Cardiovascular Surgery ● Volume 133, Number 2 539
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TXcores are much lower than what we would like to see
iven how sick they are. That is one of the reasons we
ope that working with the SRTR we can potentially
ffect what their scoring system is set at. I do not have a
ood answer for that, but I think that it is important to try
o better identify the sicker patients with pulmonary
rterial hypertension. I have talked with our pulmonolo-40 The Journal of Thoracic and Cardiovascular Surgery ● Febrhen they are at death’s door, and the potential of what
e have is perhaps 32% mortality. I am not sure.
Dr Sonett. I think part of the problem is that nobody
s able to predict ahead of time when those patients are
oing to fall off the tightrope that they have been walking
n with the ever increasing array of medications to ame-
iorate the pulmonary hypertension.ists about this, and they send the patients to us basically Dr Chang. Right.uary 2007
